Modern Drug Discovery

The advantages genetics could bring to clinical development and decision-making, as well as the next steps needed to make it a valid tool in this environment, were underscored in the recent findings of two studies performed by distinct research groups at Harvard Medical School. The studies analyzed tumor samples from lung cancer patients who had taken Iressa (gefitinib), a small-molecule targeted cancer therapy developed by AstraZeneca.

Click here for full article

To make any comments on this article, or to ask a question of the author, please contact the publisher. If you would like to submit an article please subscribe to our PL Intelligence service.

The opinions expressed in the articles published in this section do not necessarily reflect those of Pharmalicensing or UTEK Corporation. No actions including proposals to or agreements with other companies should be taken by any reader without obtaining specific business or legal advice. Neither the publisher nor the authors accept any liability for any actions or activities undertaken by any reader or other third party as a consequence of these articles or for any errors or omissions therein.